Pro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says

MT Newswires Live07-09

Pro Medicus' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.

The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.

AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging "one viewer" strategy, and its cloud partnerships.

The investment firm downgraded Pro Medicus to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650494624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 14:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650494624","market":"nz","top_or_hot":-1,"title":"Pro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.</p><p>The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.</p><p>AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging \"one viewer\" strategy, and its cloud partnerships.</p><p>The investment firm downgraded <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus Growth Not Expected to Be Impeded by Artificial Intelligence, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-09 14:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a>' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.</p><p>The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.</p><p>AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging \"one viewer\" strategy, and its cloud partnerships.</p><p>The investment firm downgraded <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4185","symbol_name":"保健护理机构","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650494624","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650494624","pubTimestamp":1783577487,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pro Medicus'  growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system  market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging \"one viewer\" strategy, and its cloud partnerships.The investment firm downgraded Pro Medicus to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4185":"保健护理机构","PME.AU":"PRO MEDICUS LTD","BK7094":"医疗保健技术","PACS":"PACS Group"},"translate_title":"杰富瑞表示，Pro Medicus的增长预计不会受到人工智能的阻碍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACS":1,"PME.AU":1},"content_text":"Pro Medicus' (ASX:PME) growth is not expected to be impeded by artificial intelligence, but at the current share price, the market seems to be assuming that the firm will have a market share of the US picture archiving and communication system (PACS) market of around 51% by fiscal year 2035, from 11%, according to a Thursday note by Jefferies.The firm's Visage PACS demonstrates class-leading low latency, which continues to drive market share gains. Large data sets, a shift to the cloud, and low growth in radiologists in the US are industry drivers over the medium-term.AI is more likely to enhance Visage's value proposition because of its server-side streaming architecture, enterprise imaging \"one viewer\" strategy, and its cloud partnerships.The investment firm downgraded Pro Medicus to hold from buy and raised the price target to AU$192.60 per share from AU$147 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650494624","isCrawlerRequest":true}